Humana’s (HUM) “Neutral” Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald reissued their neutral rating on shares of Humana (NYSE:HUM) in a research report report published on Wednesday,Benzinga reports. The brokerage currently has a $290.00 price objective on the insurance provider’s stock. Cantor Fitzgerald also issued estimates for Humana’s FY2025 earnings at $16.27 EPS.

Several other equities research analysts have also issued reports on HUM. Morgan Stanley lowered their target price on shares of Humana from $301.00 to $285.00 and set an “equal weight” rating for the company in a report on Wednesday. Truist Financial raised their target price on shares of Humana from $260.00 to $290.00 and gave the company a “hold” rating in a research report on Monday, January 6th. TD Cowen lifted their price objective on shares of Humana from $261.00 to $268.00 and gave the stock a “hold” rating in a research report on Monday, November 4th. Piper Sandler lifted their price objective on shares of Humana from $270.00 to $288.00 and gave the stock a “neutral” rating in a research report on Wednesday, January 15th. Finally, Wells Fargo & Company lowered their target price on shares of Humana from $387.00 to $290.00 and set an “overweight” rating for the company in a research note on Monday, November 4th. Nineteen analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $293.05.

Humana Stock Performance

Shares of NYSE HUM opened at $253.61 on Wednesday. The firm has a fifty day moving average price of $271.83 and a 200-day moving average price of $295.17. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.76 and a quick ratio of 1.76. The stock has a market cap of $30.54 billion, a PE ratio of 22.46, a price-to-earnings-growth ratio of 2.11 and a beta of 0.56. Humana has a 1 year low of $213.31 and a 1 year high of $406.46.

Humana (NYSE:HUM) last posted its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share for the quarter, beating the consensus estimate of ($2.26) by $0.10. Humana had a net margin of 1.18% and a return on equity of 13.20%. Equities analysts anticipate that Humana will post 16.11 earnings per share for the current fiscal year.

Insider Activity at Humana

In related news, insider Timothy S. Huval sold 3,703 shares of the company’s stock in a transaction dated Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total value of $948,930.78. Following the completion of the sale, the insider now owns 8,181 shares of the company’s stock, valued at approximately $2,096,463.06. This represents a 31.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. 0.32% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Humana

A number of hedge funds have recently modified their holdings of the company. Vanguard Group Inc. grew its holdings in shares of Humana by 15.8% in the fourth quarter. Vanguard Group Inc. now owns 12,829,210 shares of the insurance provider’s stock valued at $3,254,899,000 after purchasing an additional 1,751,857 shares during the period. Dodge & Cox lifted its position in Humana by 106.7% in the fourth quarter. Dodge & Cox now owns 10,198,040 shares of the insurance provider’s stock valued at $2,587,345,000 after buying an additional 5,264,045 shares during the last quarter. State Street Corp lifted its position in Humana by 1.0% in the third quarter. State Street Corp now owns 5,357,420 shares of the insurance provider’s stock valued at $1,701,582,000 after buying an additional 53,272 shares during the last quarter. Pzena Investment Management LLC lifted its position in Humana by 44.0% in the fourth quarter. Pzena Investment Management LLC now owns 3,609,382 shares of the insurance provider’s stock valued at $915,736,000 after buying an additional 1,103,132 shares during the last quarter. Finally, FMR LLC lifted its position in Humana by 23.4% in the third quarter. FMR LLC now owns 3,388,859 shares of the insurance provider’s stock valued at $1,073,387,000 after buying an additional 643,291 shares during the last quarter. Hedge funds and other institutional investors own 92.38% of the company’s stock.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.